The CACNA1A Foundation is excited to share that data from the CACNA1A Disease Concept Model Study was presented for the first time at the American Epilepsy Society meeting. Led by Dr. Pangkong Fox and Ananya Terala from COMBINEDBrain, the study identified key symptoms impacting quality of life, including decreased expressive language, gastrointestinal issues, and sleep disorders—many not previously reported.

The findings highlight significant caregiver challenges, patient hospitalization rates, and the need for comprehensive treatment approaches. Next steps include publishing the full study and presenting it to the FDA in 2025, marking a critical milestone for advancing awareness and treatment opportunities.

Donna Schaare returned to school to pursue a PhD to better support her son, Jon, who faces CACNA1A-related hemiplegic migraines and epilepsy. She recently published her dissertation, “Living with" CACNA1A-related Hemiplegic Migraine, a disease concept model that goes beyond clinical data by capturing the lived experiences of patients and their families. Donna extends a heartfelt thank you to this community and to everyone who participated. "You are the heroes; hopefully, what we learned will bring us closer to a cure."

In June 2024, the CACNA1A Foundation submitted a proposal to the CDC to obtain an ICD-10 code specific to CACNA1A-related neurodevelopmental disorder (CACNA1A-NDD), as no current code adequately captures the complex and lifelong clinical manifestations of the disorders associated with this rare genetic disease.  

As explained in the proposal, a unique ICD-10 code will serve to track the quality, safety, and efficacy of care for individuals with CACNA1A- NDD. It will enable better identification and tracking of symptoms and co-morbidities across genotypes and is critical for tracking the progression of CACNA1A-NDD phenotypes with age. 

The CACNA1A Foundation held its third annual Research Roundtable on July 18, 2024. The event was hosted by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), the largest funding body for scientific research in the United States. Fifty attendees from the CACNA1A Research Network, including grant program managers from NINDS, Foundation Board and Leadership Team members, industry representatives, researchers, and clinicians from around the world, gathered to discuss accelerating the pathway to clinical trials for CACNA1A-related disorders. The roundtable began with a focus on what the CACNA1A community has identified as priority symptoms and treatment gaps. The four sessions featured 12 speakers presenting on outcomes from three CACNA1A working groups that were launched last fall to address the community’s needs: CACNA1A Natural History Study/Biomarkers, CACNA1A Variant Classification, and the Preclinical to Clinical Pathway. 

Identifying biomarkers, outcome measures, and endpoints hinges on the partnership of the CACNA1A community. This blog post explains what they are and the importance of finding the right biomarkers and endpoints for CACNA1A-related diseases. The CACNA1A Foundation is immensely grateful to all the patients and families for their unwavering support in helping us find the best methods of testing a potential treatment and getting it approved by the FDA. Together, we are paving the way towards a better understanding and treatment of CACNA1A-related disorders.

Babies with feeding issues, problems with movement or muscle tone, or who have missed developmental milestones may benefit from genetic testing. Project FIND-OUT is an important research project to help parents get answers about potential genetic causes of their baby’s symptoms. Learn more about Project FIND-OUT, which provides free genetic counseling and testing for infants in the USA between the ages of 3-12 months, and whether your baby might be eligible.

When thinking about my daughter Miren, who has a CACNA1a variant, I often find myself repeating Joseph Campbell’s quote, “We must get rid of the life we had planned in order to have the life that is waiting for us.” My expectations of motherhood and my duty as a parent have changed since Miren’s diagnosis. Before her birth, I thought success in parenting meant raising children who could provide for themselves, contribute to the greater good, and do the same for their children. Miren has already left a positive mark on the world; she shows her peers what rare disease looks like, that perseverance is cool, and that everyone deserves a turn on the swing.

The CACNA1A Foundation Board of Directors is proud to present our 2023 Impact Report. As you will see, 2023 was a year of significant progress and we are thrilled to share our collective achievements. We hope you will take the time to read the report and that it inspires you to join us if you have not already. We are #strongertogether!

The CACNA1A Foundation hosted its second Research Roundtable: Collaborating to Accelerate the Path to CACNA1A Clinical Trials on October 9-10, 2023. The overarching purpose was to exchange ideas and build collaborations among the CACNA1A Research Network to develop CACNA1A-specific treatments and push them into clinical trials for FDA approval.

In 2021, the CACNA1A Foundation received a 3-year Rare As One (RAO) grant from the Chan Zuckerberg Initiative (CZI) to build our capacity. In September 2023, we were invited to attend the Chan Zuckerburg Initiative’s (CZI) Science in Society Annual meeting held in Newport Beach, California. There, we joined representatives from other organizations who had received funding from CZI to learn, build community, and celebrate wins. Board members Lisa Manaster and Sunitha Malepati were joined at the meeting by Pangkong Fox, PhD, the CACNA1A Foundation’s Science Engagement Director, who was invited to speak about our patient-driven initiatives with COMBINEDBrain and Rare-X.

The CACNA1A Foundation hosted its first Research Roundtable: Collaborating to Accelerate the Path to CACNA1A Clinical Trials on September 22nd and 23rd at the New York Academy of Medicine in New York City. It was a historic event with 37 of the world's experts on CACNA1A, ion channels, genetics, ataxia, epilepsy, hemiplegic migraine, and eye movement disorders convening for the first time ever. Goals included identifying gaps in understanding how CACNA1A variants lead to disease and developing therapeutic treatments that will have the greatest impact on those living with CACNA1A-related disorders.

The two-day conference was divided into three sessions, each with four presentations, followed by a facilitated discussion. The meeting closed with a wrap-up session focused on next steps for the CACNA1A Foundation and the CACNA1A Research Network to move treatments into the clinical trial pipeline. Read on for a summary of the presentations.

Whether it’s a problem with a school, health care provider or insurance company, recreational program, or even a city sidewalk, U.S. laws are strong and provide ample means of rights enforcement. Leading up to passage of the Americans with Disabilities Act (ADA) in 1990, Congress recognized that children and adults with disabilities have historically been marginalized, if not institutionalized. The “medical model” of disability had governed for decades, focusing on medical needs, “cures,” and other non-rights-based notions. The passage of the ADA signaled the modern era – an era of empowerment and self-determination, in which people with disabilities are treated with respect and dignity and afforded enforceable rights to live independently and on their own terms. We all deserve nothing less.

While many children experience eating issues when they are young, children with developmental disabilities have much higher rates of "selective eating" than their typical peers. CACNA1A disorders can be associated with feeding issues as a result of autism, sensory processing deficits, motor impairments due to ataxia, or food intolerances. CACNA1A mom, Celine Carayon, explains that what she thought were “latching” and “reflux problems” when her daughter was a baby turned out to be connected to her congenital ataxia, which has also affected her speech. Celine is not alone in this struggle: in fact, 80% of kids with special needs experience some sort of feeding difficulty. Celine was excited to discover that the NAPA Center (NAPA) offers a number of free online resources and tips that can be helpful to CACNA1A families like hers. While NAPA focuses on early intervention, these are life-long issues and may be of interest to parents of older children or adults.

Would you like a better future for your child? Do you want scientists and pharma to invest in our disease? For researchers to find the small molecule or gene therapy that could help you, your child, or your family member? If so, don't limit the data available to researchers – they need your information!

Whether it’s a problem with a school, health care provider or insurance company, recreational program, or even a city sidewalk, U.S. laws are strong and provide ample means of rights enforcement. Leading up to passage of the Americans with Disabilities Act (ADA) in 1990, Congress recognized that children and adults with disabilities have historically been marginalized, if not institutionalized. The “medical model” of disability had governed for decades, reducing folks with disabilities to the pitied who needed to be taken care of, cured, or put in a home. The passage of the ADA signaled the modern era – a rights-based model under which people with disabilities are treated with respect and dignity, and afforded enforceable rights to live independently and on their own terms.

In the United States, almost 40% of our population is fully vaccinated. Cities and towns are starting to lift restrictions, and we are beginning to see the light at the end of the tunnel. As a rare disease community, we should be relieved, yet this step brings with it increased anxiety and challenges; We are eager to see our friends and families, yet there is a need to balance security with socialization. With the recent approval by the FDA of the Pfizer-BioNTech COVID-19 vaccine for children aged 12 - 15, many families are wondering if they should vaccinate their children. The CDC is recommending the vaccine for this age group.

The CACNA1A Foundation is excited to announce that we have been accepted as a member of COMBINEDbrain a non-profit consortium of 25 patient-advocacy foundations, each representing a different rare genetic neurodevelopmental disorder. COMBINEDBrain is devoted to speeding the path to clinical trial readiness for severe rare neurodevelopmental disorders by pooling efforts, studies and data.

While many children experience eating issues when they are young, children with developmental disabilities have much higher rates of "selective eating" than their typical peers. CACNA1A disorders can be associated with feeding issues as a result of autism, sensory processing deficits, motor impairments due to ataxia, or food intolerances. CACNA1A mom, Celine Carayon, explains that what she thought were “latching” and “reflux problems” when her daughter was a baby turned out to be connected to her congenital ataxia, which has also affected her speech. Celine is not alone in this struggle: in fact, 80% of kids with special needs experience some sort of feeding difficulty. Celine was excited to discover that the NAPA Center (NAPA) offers a number of free online resources and tips that can be helpful to CACNA1A families like hers. While NAPA focuses on early intervention, these are life-long issues and may be of interest to parents of older children or adults.

The world of cortical vision impairment (CVI) introduced my family and me to a whole new “language” regarding vision. We learned that for children who are born with CVI, getting this diagnosis early in life is crucial. It’s critical for any child diagnosed with CVI to be assessed with the CVI Range as early as possible because it provides the framework for individualized interventions.

Our family was catapulted into the world of cortical vision impairment (CVI) after our youngest daughter, Addilynn, experienced a status epilepticus event that resulted in her suffering a traumatic brain injury (TBI) at the age of three.